(Q37805634)

23 August 2017

Doping and musculoskeletal system: short-term and long-lasting effects of doping agents (English)

1 reference

23 August 2017

Chara Spiliopoulou

2

0 references

author name string

Dimitrios D Nikolopoulos

series ordinal

1

1 reference

PubMed ID

21039821

23 August 2017

Stamatios E Theocharis

series ordinal

3

1 reference

23 August 2017

6 October 2010

1 reference

Fundamental and Clinical Pharmacology

23 August 2017

1 reference

23 August 2017

25

1 reference

23 August 2017

5

1 reference

23 August 2017

535-563

1 reference

The history of doping and growth hormone abuse in sport

23 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Hormone abuse in sports: the antidoping perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

The decline of androgen levels in elderly men and its clinical and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Abuse of anabolic androgenic steroids and related substances in sport and exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Testosterone precursors: use and abuse in pediatric athletes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Effects of androgenic-anabolic steroids in athletes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Androgenic-anabolic steroids and the Olympic Games

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Androgen abuse in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Anabolic androgenic steroids: a survey of 500 users

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Anabolic-androgenic steroids and liver injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Muscular strength, body composition and health responses to the use of testosterone enanthate: a double blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Bodybuilders' body composition: effect of nandrolone decanoate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

"Anabolic" effects of methandienone in men undergoing athletic training

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Body composition and anthropometry in bodybuilders: regional changes due to nandrolone decanoate administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Effects of anabolic steroids on the muscle cells of strength-trained athletes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Testosterone-induced muscle hypertrophy is associated with an increase in satellite cell number in healthy, young men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Triceps rupture. A case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Spontaneous rupture of the anterior cruciate ligament after anabolic steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Rhabdomyolysis of the deltoid muscle in a bodybuilder using anabolic-androgenic steroids: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Exertional rhabdomyolysis in a body builder abusing anabolic androgenic steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Discovery and therapeutic promise of selective androgen receptor modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Identification of anabolic selective androgen receptor modulators with reduced activities in reproductive tissues and sebaceous glands

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Therapeutic potential of the SARMs: revisiting the androgen receptor for drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Imaging metastatic bone disease from carcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Indirect androgen doping by oestrogen blockade in sports

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Gonadotropins in doping: pharmacological basis and detection of illicit use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Clinical review: The rationale for banning human chorionic gonadotropin and estrogen blockers in sport

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Human chorionic gonadotrophin and sport

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Hypophysial Responses to Continuous and Intermittent Delivery of Hypothalamic Gonadotropin-Releasing Hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

SERMs: meeting the promise of multifunctional medicines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Selective estrogen-receptor modulators and antihormonal resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

The effect of aromatase inhibitors on bone metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Aromatase inhibitor-associated bone loss: clinical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Deletion of estrogen receptors reveals a regulatory role for estrogen receptors-beta in bone remodeling in females but not in males

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Endogenous estrogen deficiency reduces proliferation and enhances apoptosis-related death in vascular smooth muscle cells: insights from the aromatase-knockout mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Therapeutic uses of aromatase inhibitors in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Update on the role of aromatase inhibitors in growth disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Structure-activity relationships of synthetic progestins in a yeast-based in vitro androgen bioassay

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Effect of a synthetic progestin on the exercise status of sedentary young women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Role of cytokines in postmenopausal bone loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Comparative clinical pharmacology and pharmacokinetic interactions of aromatase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Clinical pharmacological aspects of growth hormone administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Growth hormone in sport: beyond Beijing 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

A robust test for growth hormone doping--present status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Growth hormone and the adolescent athlete: What are the data for its safety and efficacy as an ergogenic agent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Correlations of growth hormone (GH) and insulin-like growth factor I (IGF-I): effects of exercise and abuse by athletes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Insulin and insulin-like growth factor-I enhance human skeletal muscle protein anabolism during hyperaminoacidemia by different mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Insulin, growth hormone and sport

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

High Dose Growth Hormone Exerts an Anabolic Effect at Rest and during Exercise in Endurance-Trained Athletes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Cloning and characterization of an IGF-1 isoform expressed in skeletal muscle subjected to stretch.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Expression of IGF-I splice variants in young and old human skeletal muscle after high resistance exercise.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Systematic review: the effects of growth hormone on athletic performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Human growth hormone doping in sport

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Challenges in detecting the abuse of growth hormone in sport

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Growth hormone abuse: methods of detection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Validation of the growth hormone (GH)-dependent marker method of detecting GH abuse in sport through the use of independent data sets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Influence of ethnicity on IGF-I and procollagen III peptide (P-III-P) in elite athletes and its effect on the ability to detect GH abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Ghrelin is a growth-hormone-releasing acylated peptide from stomach

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Development of growth hormone secretagogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

The physiology of growth hormone and sport

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Physiological and pharmacological basis for the ergogenic effects of growth hormone in elite sports

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Growth hormone, IGF-I and insulin and their abuse in sport.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Systematic review: the safety and efficacy of growth hormone in the healthy elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

One year of GH replacement therapy with a fixed low-dose regimen improves body composition, bone mineral density and lipid profile of GH-deficient adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

The growth hormone/insulin-like growth factor-I axis in exercise and sport

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Cardiovascular effects of prolonged growth hormone replacement in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Acute growth hormone administration causes exaggerated increases in plasma lactate and glycerol during moderate to high intensity bicycling in trained young men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Effects of high-dose growth hormone on glucose and glycerol metabolism at rest and during exercise in endurance-trained athletes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Growth factor delivery methods in the management of sports injuries: the state of play

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

The Roles of Growth Factors in Tendon and Ligament Healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Platelet-rich plasma: evidence to support its use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

New insights into and novel applications for platelet-rich fibrin therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

New therapeutic approaches for management of sport-induced muscle strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Platelet-rich plasma: from basic science to clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

The biology of platelet-rich plasma and its application in trauma and orthopaedic surgery: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Immunohistochemical study of angiogenesis after local administration of platelet-rich plasma in a patellar tendon defect

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Platelet-rich plasma enhances the initial mobilization of circulation-derived cells for tendon healing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Platelet-rich plasma injection for chronic Achilles tendinopathy: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Treatment of chronic elbow tendinosis with buffered platelet-rich plasma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Comparison of surgically repaired Achilles tendon tears using platelet-rich fibrin matrices.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Autologous blood injections for refractory lateral epicondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Treatment of tendon and muscle using platelet-rich plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Platelet-rich plasma: new clinical application: a pilot study for treatment of jumper's knee.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Strategies in biologic augmentation of rotator cuff repair: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

The use of platelet-rich plasma in arthroscopy and sports medicine: optimizing the healing environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Platelet-rich therapies in the treatment of orthopaedic sport injuries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Platelet rich plasma injection grafts for musculoskeletal injuries: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Could platelet rich plasma have effects on systemic circulating growth factors and cytokine release in orthopaedic applications?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Erythropoiesis-stimulating agents and other methods to enhance oxygen transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Testing for recombinant erythropoietin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Blood doping : infusions, erythropoietin and artificial blood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Cardiovascular toxicities of performance-enhancing substances in sports

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Erythropoietin administration does not influence the GH--IGF axis or makers of bone turnover in recreational athletes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Effects of recombinant human erythropoietin on mandibular distraction osteogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Erythropoietin improves functional and histological recovery of traumatized skeletal muscle tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Erythropoietin receptor in human skeletal muscle and the effects of acute and long-term injections with recombinant human erythropoietin on the skeletal muscle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Activation of the erythropoietin receptor in human skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Erythropoietin improves skeletal muscle microcirculation and tissue bioenergetics in a mouse sepsis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Muscle glycogen synthesis before and after exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Bodybuilders find it easy to obtain insulin to help them in training

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Insulin as a drug of abuse in body building

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Characterization of beta 1- and beta 2-adrenoceptors in rat skeletal muscles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Beta 2-agonist administration reverses muscle wasting and improves muscle function in aged rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

The abuse of doping agents in competing body builders in Flanders (1988-1993).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

The rush to adrenaline: drugs in sport acting on the beta-adrenergic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Doping dose of salbutamol and exercise: deleterious effect on cancellous and cortical bones in adult rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Anabolic effects of a non-myotoxic dose of the beta2-adrenergic receptor agonist clenbuterol on rat plantaris muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Multiple actions of beta-adrenergic agonists on skeletal muscle and adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Skeletal muscle hypertrophy and anti-atrophy effects of clenbuterol are mediated by the beta2-adrenergic receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Beta2-adrenoceptor agonist fenoterol enhances functional repair of regenerating rat skeletal muscle after injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Clenbuterol treatment affects myosin heavy chain isoforms and MyoD content similarly in intact and regenerated soleus muscles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Expression profiling of skeletal muscle following acute and chronic beta2-adrenergic stimulation: implications for hypertrophy, metabolism and circadian rhythm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Asthmatic drugs and competitive sport. An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Can asthma treatment in sports be doping? The effect of the rapid onset, long-acting inhaled beta2-agonist formoterol upon endurance performance in healthy well-trained athletes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Albuterol and exercise effects on ankle extensor strength during 40 days of unloading

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Effect of salbutamol on muscle strength and endurance performance in nonasthmatic men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Pilot trial of albuterol in Duchenne and Becker muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Characterization of beta-adrenergic receptors on rat and human osteoblast-like cells and demonstration that beta-receptor agonists can stimulate bone resorption in organ culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Adrenergic regulation of bone metabolism: possible involvement of sympathetic innervation of osteoblastic and osteoclastic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Effects of beta-adrenergic agonists on bone-resorbing activity in human osteoclast-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Bone's mechanostat: A 2003 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Inhibited longitudinal growth of bones in young male rats by clenbuterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Leptin regulates bone formation via the sympathetic nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Severe bone alterations under beta2 agonist treatments: bone mass, microarchitecture and strength analyses in female rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Influence of clenbuterol on bone metabolism in exercised or sedentary rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Doping dose of salbutamol and exercise training: impact on the skeleton of ovariectomized rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Use of beta-blockers and risk of fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Effects of a beta-blocker on bone turnover in normal postmenopausal women: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Effects of antihypertensive drug treatments on fracture outcomes: a meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Glucocorticosteroids in football: use and misuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Detection of physiological concentrations of cortisol and cortisone in human hair

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Complications associated with the use of corticosteroids in the treatment of athletic injuries

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Intra-articular corticosteroids. Guide to selection and indications for use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Intra-articular therapy in osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

In whom and how to prevent glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Proposals for prevention and management of steroid-induced osteoporosis in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Side effects of short-term oral corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

The effects of corticosteroids on bone: osteonecrosis (avascular necrosis of the bone).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Partial and complete ruptures of the Achilles tendon and local corticosteroid injections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Patellar tendon ruptures in weight lifters after local steroid injections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Common extensor tendon rupture following corticosteroid injection for lateral tendinosis of the elbow

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Complications of plantar fascia rupture associated with corticosteroid injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Plantar fascia rupture associated with corticosteroid injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Glucocorticoids inhibit tenocyte proliferation and Tendon progenitor cell recruitment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Inhibition of tendon cell migration by dexamethasone is correlated with reduced alpha-smooth muscle actin gene expression: a potential mechanism of delayed tendon healing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

NS-398, a cyclooxygenase-2-specific inhibitor, delays skeletal muscle healing by decreasing regeneration and promoting fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Central nervous system stimulants and sport practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Effects of ephedrine, caffeine, and their combination on muscular endurance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Enhanced stimulant and metabolic effects of combined ephedrine and caffeine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Cardiotoxic effects of cocaine and anabolic-androgenic steroids in the athlete.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

21 January 2018

Cocaine and the heart

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Myostatin: a modulator of skeletal-muscle stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Functional improvement of dystrophic muscle by myostatin blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Myostatin inhibition: a potential performance enhancement strategy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

The growth factor myostatin, a key regulator in skeletal muscle growth and homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Myostatin mutation associated with gross muscle hypertrophy in a child

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Regulation of myostatin activity and muscle growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Anabolic steroid-induced rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

Use of beta-2 agonists and risk of hip/femur fracture: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2010.00881.X

10.1111/J.1472-8206.2010.00881.X

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

21039821